Edition:
United States

Johnson & Johnson (JNJ.N)

JNJ.N on New York Stock Exchange

137.93USD
20 Nov 2017
Change (% chg)

$-0.07 (-0.05%)
Prev Close
$138.00
Open
$138.15
Day's High
$138.56
Day's Low
$137.75
Volume
1,449,826
Avg. Vol
1,698,793
52-wk High
$144.34
52-wk Low
$109.32

Chart for

About

Johnson & Johnson is a holding company, which is engaged in the research and development, manufacture and sale of a range of products in the healthcare field. It operates through three segments: Consumer, Pharmaceutical and Medical Devices. Its primary focus is products related to human health and well-being. The Consumer... (more)

Overall

Beta: 0.82
Market Cap(Mil.): $370,739.81
Shares Outstanding(Mil.): 2,686.52
Dividend: 0.84
Yield (%): 2.43

Financials

  Industry Sector
P/E (TTM): -- 31.35 15.79
EPS (TTM): -- -- --
ROI: -- 15.11 12.01
ROE: -- 16.52 15.91

Johnson & Johnson hit with $247 million verdict in hip implant trial

NEW YORK A federal jury in Dallas on Thursday ordered Johnson & Johnson and its DePuy Orthopaedics unit to pay $247 million to six patients who said they were injured by defective Pinnacle hip implants.

Nov 16 2017

Johnson & Johnson wins California lawsuit claiming asbestos in talc caused cancer

A California jury on Thursday ruled in favor of Johnson & Johnson in a lawsuit by a woman who said she developed the cancer mesothelioma after being exposed to asbestos in the company's talc-based products including J&J's Baby Powder.

Nov 16 2017

UPDATE 3-J&J wins California lawsuit claiming asbestos in talc caused cancer

Nov 16 A California jury on Thursday ruled in favor of Johnson & Johnson in a lawsuit by a woman who said she developed the cancer mesothelioma after being exposed to asbestos in the company's talc-based products including J&J's Baby Powder.

Nov 16 2017

UPDATE 2-Johnson & Johnson hit with $247 mln verdict in hip implant trial

NEW YORK, Nov 16 A federal jury in Dallas on Thursday ordered Johnson & Johnson and its DePuy Orthopaedics unit to pay $247 million to six patients who said they were injured by defective Pinnacle hip implants.

Nov 16 2017

J&J wins Calif. lawsuit claiming asbestos in talc caused cancer

Nov 16 A California jury on Thursday ruled in favor of Johnson & Johnson in a lawsuit by a woman who said she developed the cancer mesothelioma after being exposed to asbestos in the company's talc-based products including J&J's Baby Powder.

Nov 16 2017

Johnson & Johnson hit with $247 mln verdict in hip implant trial

NEW YORK, Nov 16 A federal jury in Dallas on Thursday ordered Johnson & Johnson and its DePuy Orthopaedics unit to pay $247 million to six patients who said they were injured by defective Pinnacle hip implants.

Nov 16 2017

Janssen drops U.S. lawsuit against Samsung Bioepis' Remicade copy

SEOUL A unit of healthcare conglomerate Johnson & Johnson has dropped a lawsuit it filed to block a copy of its rheumatoid arthritis drug Remicade produced by South Korea's Samsung Bioepis Co Ltd from being sold in the United States.

Nov 14 2017

Janssen drops U.S. lawsuit against Samsung Bioepis' Remicade copy

SEOUL, Nov 14 A unit of healthcare conglomerate Johnson & Johnson has dropped a lawsuit it filed to block a copy of its rheumatoid arthritis drug Remicade produced by South Korea's Samsung Bioepis Co Ltd from being sold in the United States.

Nov 14 2017

BRIEF-Zymeworks announces license agreement with Johnson & Johnson Innovation

* Zymeworks announces license agreement with Johnson & Johnson Innovation to develop and commercialize next generation bispecific antibody therapeutics

Nov 13 2017

J&J's Ethicon cleared of liability in another federal pelvic mesh trial

Johnson & Johnson subsidiary Ethicon was not liable for the injuries that a Texas woman blamed on the company's pelvic mesh device, a federal jury decided on Thursday.

Nov 10 2017

Earnings vs. Estimates